Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
The analysis of long-term investment activity ratios reveals a general contraction in asset and equity efficiency from 2016 to 2020. While specific fixed asset metrics show volatility, the overarching trend across total assets and equity suggests a decline in the revenue-generating capacity of the investment base.
- Net Fixed Asset Turnover
- The standard net fixed asset turnover exhibited volatility, declining initially to 2.96 in 2017 before peaking at 3.99 in 2019 and settling at 3.51 in 2020. Conversely, the turnover ratio inclusive of right-of-use assets showed a significant downward trend starting in 2019, falling to 2.23 by 2020. This divergence suggests that the recognition of leased assets has increased the asset base more rapidly than the corresponding growth in revenue.
- Total Asset Turnover
- A persistent downward trend is observed in total asset turnover, which decreased steadily from 0.56 in 2016 to 0.43 in 2020. This decline indicates a reduction in the efficiency with which the total asset portfolio is utilized to generate sales over the five-year period.
- Equity Turnover
- Equity turnover experienced a consistent and steep decline, falling from 1.09 in 2016 to 0.69 in 2020. This pattern reflects a growing disparity between the accumulation of equity and the growth of net sales, signaling a decrease in the productivity of shareholders' capital in driving top-line growth.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Net Fixed Asset Turnover
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Property and equipment, net | 922) | 889) | 1,075) | 931) | 713) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 3.51 | 3.99 | 3.10 | 2.96 | 3.36 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 3,239 ÷ 922 = 3.51
2 Click competitor name to see calculations.
The analysis of long-term investment activity indicates a period of variable efficiency in asset utilization between 2016 and 2020. While revenue grew consistently from 2016 through 2019, the relationship between fixed asset investment and revenue generation showed significant volatility, reflecting shifting operational dynamics.
- Revenue and Asset Base Dynamics
- Revenue increased from 2,398 million US dollars in 2016 to a peak of 3,543 million US dollars in 2019, before declining to 3,239 million US dollars in 2020. During the same period, net property and equipment grew from 713 million US dollars in 2016 to a peak of 1,075 million US dollars in 2018, followed by a decrease to 889 million US dollars in 2019 and a slight increase to 922 million US dollars in 2020.
- Net Fixed Asset Turnover Trends
- The net fixed asset turnover ratio experienced an initial decline from 3.36 in 2016 to 2.96 in 2017, coinciding with a period of asset expansion. The ratio then improved to 3.10 in 2018 and reached a peak of 3.99 in 2019. This peak was the result of the simultaneous achievement of maximum revenue and a reduction in the net fixed asset base. By 2020, the ratio contracted to 3.51, reflecting the combined effect of lower revenue and a modest increase in net property and equipment.
- Operational Efficiency Insights
- The fluctuations in the turnover ratio suggest a cycle of investment and optimization. The decline observed in 2017 indicates a phase where investment in fixed assets outpaced revenue growth. Conversely, the surge in 2019 indicates a period of high asset productivity, where the organization generated significantly more revenue per unit of net fixed assets, suggesting optimized capacity utilization or a strategic reduction in the asset base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Illumina Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Property and equipment, net | 922) | 889) | 1,075) | 931) | 713) | |
| Operating lease right-of-use assets | 532) | 555) | —) | —) | —) | |
| Property and equipment, net (including operating lease, right-of-use asset) | 1,454) | 1,444) | 1,075) | 931) | 713) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 2.23 | 2.45 | 3.10 | 2.96 | 3.36 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property and equipment, net (including operating lease, right-of-use asset)
= 3,239 ÷ 1,454 = 2.23
2 Click competitor name to see calculations.
Between 2016 and 2020, a consistent decline in asset utilization efficiency is observed, as evidenced by the downward trajectory of the net fixed asset turnover ratio. While revenue experienced an overall increase for the majority of the period, the growth in net fixed assets, including right-of-use assets, outpaced revenue generation, leading to a diminished return on long-term investments.
- Revenue Performance
- Revenue exhibited a growth trend from 2016 through 2019, rising from 2,398 million US$ to a peak of 3,543 million US$. However, this growth trend reversed in 2020, with revenue declining to 3,239 million US$, marking the first contraction in the observed five-year period.
- Fixed Asset Expansion
- Net fixed assets, inclusive of operating lease right-of-use assets, grew steadily and significantly throughout the period. Assets increased from 713 million US$ in 2016 to 1,454 million US$ in 2020, representing more than a twofold increase in the company's long-term asset base.
- Net Fixed Asset Turnover Ratio Analysis
- The net fixed asset turnover ratio decreased from 3.36 in 2016 to 2.23 in 2020. A notable acceleration in this decline occurred between 2018 and 2019, where the ratio dropped from 3.10 to 2.45, coinciding with a substantial increase in property and equipment. The continued decline into 2020 reflects a combination of expanding asset costs and contracting revenue, indicating that each dollar invested in fixed assets is generating progressively less revenue.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Total Asset Turnover
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Total assets | 7,585) | 7,316) | 6,959) | 5,257) | 4,281) | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.43 | 0.48 | 0.48 | 0.52 | 0.56 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Total asset turnover = Revenue ÷ Total assets
= 3,239 ÷ 7,585 = 0.43
2 Click competitor name to see calculations.
Between 2016 and 2020, a persistent decline in asset utilization efficiency is observed. While the organization expanded its asset base and experienced initial revenue growth, the proportionality between investment and output shifted unfavorably over the five-year period.
- Revenue Performance
- Revenue demonstrated a positive trajectory from 2016 to 2019, rising from US$ 2,398 million to a peak of US$ 3,543 million. However, this growth trend reversed in 2020, with revenue contracting to US$ 3,239 million, representing a decline of approximately 8.6% from the previous year.
- Asset Accumulation
- Total assets increased consistently throughout the analyzed period. Starting at US$ 4,281 million in 2016, the asset base grew to US$ 7,585 million by 2020. The most significant expansion occurred between 2017 and 2018, where assets grew by over 32%, indicating a period of aggressive investment in the company's infrastructure or acquisitions.
- Total Asset Turnover Trend
- The total asset turnover ratio exhibited a steady downward trend, decreasing from 0.56 in 2016 to 0.43 in 2020. This decline indicates that the company generated progressively less revenue for every dollar of assets held. The ratio remained stagnant at 0.48 during 2018 and 2019, suggesting a temporary alignment between asset growth and revenue gains, but the subsequent drop in 2020 underscores a widening gap between invested capital and resulting sales output.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Equity Turnover
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Total Illumina stockholders’ equity | 4,694) | 4,613) | 3,758) | 2,749) | 2,197) | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 0.69 | 0.77 | 0.89 | 1.00 | 1.09 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Equity turnover = Revenue ÷ Total Illumina stockholders’ equity
= 3,239 ÷ 4,694 = 0.69
2 Click competitor name to see calculations.
Between 2016 and 2020, a consistent decline in equity turnover is observed, signaling a reduction in the efficiency with which shareholders' equity is utilized to generate revenue. Although both revenue and total equity experienced overall growth during this period, the rate of equity accumulation significantly outpaced the growth in top-line earnings.
- Revenue Performance
- Revenue exhibited a general upward trajectory from 2016 through 2019, increasing from US$ 2,398 million to a peak of US$ 3,543 million. A reversal of this trend occurred in 2020, where revenue declined to US$ 3,239 million.
- Stockholders' Equity Growth
- Total stockholders' equity grew steadily and aggressively throughout the analyzed period. Starting at US$ 2,197 million in 2016, the equity base increased annually to reach US$ 4,694 million by December 31, 2020, representing a total increase of approximately 114%.
- Equity Turnover Trend
- The equity turnover ratio decreased consecutively each year, falling from 1.09 in 2016 to 0.69 in 2020. This persistent downward trend indicates that the company generated progressively less revenue per dollar of equity. The deterioration of the ratio is a direct result of the capital base expanding more rapidly than the company's ability to scale its revenue.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?